THUNDER BAY, Ontario, Canada--(BUSINESS WIRE)--Mitomics, world leader in the research and development of mitochondrial genome-based products, today announced it has entered into a non-exclusive licensing agreement with QDx Pathology Services to develop, market and process the QPredict™ Prostate Mitomic Test. The product will be based on the mitochondrial marker behind Mitomics’ currently marketed Prostate Core Mitomic Test™ (PCMT™); QDx will leverage its existing network of urologists, pathologists and processing centers to expand the availability of the technology across the United States.
